Ex­clu­sive: Sanofi to close Dutch NK cell ther­a­py biotech ac­quired in 2020

Sanofi is part­ing ways with the nat­ur­al killer cell com­pa­ny Kiadis, three and a half years af­ter buy­ing it for $357 mil­lion.

The move was qui­et­ly an­nounced via an April 8 up­date to a clin­i­cal tri­al for SAR445419, an off-the-shelf nat­ur­al killer cell ther­a­py in de­vel­op­ment for re­lapsed/re­frac­to­ry acute myeloid leukemia. The Phase 1 study was ap­par­ent­ly ter­mi­nat­ed due to a “di­vest­ment of Kiadis,” per the up­date to the US clin­i­cal tri­als data­base.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER